← Leaderboards
Amy L Hartman
University Of Pittsburgh At Pittsburgh
$17,863,276
Attributed
$20,874,619
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.1M · FY2015–25$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,874,619 · 9
By mechanism
R01$13,644,103 · 5
U19$5,220,489 · 1
R56$1,149,175 · 1
R21$860,852 · 2
Top collaborators
- Gaya K. Amarasinghe8 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Natasha Louise Tilston-Lunel$749,069
- Cynthia McMillen$374,514
- Sonya B. Borrero$6,540,731
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusInfectionRift Valley Fever VirusAnimalsPathogenCellsDisease OutbreaksAfricaVirulentCulicidaeVaccinesVirus DiseasesTropismPreventPathogenesisLivestockNeuronsEpidemicEncephalitisViralTissuesIn VitroNational Institute Of Allergy And Infectious DiseaseImmune
Grant awards (28)
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses$767,375
R01 · FY2025 · AI
Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses$757,645
R01 · FY2025 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$731,052
R01 · FY2025 · AI
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses$608,641
R01 · FY2025 · AI · contact PI
Design and development of generalizable countermeasures against prototype Phenuiviruses$5,220,489
U19 · FY2024 · AI · contact PI
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses$767,375
R01 · FY2024 · AI
Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses$757,645
R01 · FY2024 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$735,323
R01 · FY2024 · AI
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses$634,196
R01 · FY2024 · AI · contact PI
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses$783,556
R01 · FY2023 · AI
Mechanisms of Neuronal Infection by Prototype Emerging Bunyaviruses$772,395
R01 · FY2023 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$739,505
R01 · FY2023 · AI
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses$632,888
R01 · FY2023 · AI · contact PI
Comparative Analysis of Bunyavirus Neuropathogenesis$1,149,175
R56 · FY2022 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$742,007
R01 · FY2022 · AI
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses$483,301
R01 · FY2022 · AI · contact PI
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus$195,050
R21 · FY2022 · AI · contact PI
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis$756,494
R01 · FY2021 · AI
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses$634,557
R01 · FY2021 · AI · contact PI
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever$334,964
R01 · FY2021 · NS · contact PI
Role of the novel entry factor Lrp1 in in vivo tropism and pathogenesis of Rift Valley fever virus$246,950
R21 · FY2021 · AI · contact PI
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses$677,858
R01 · FY2020 · AI · contact PI
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever$333,894
R01 · FY2020 · NS · contact PI
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever$332,922
R01 · FY2019 · NS · contact PI
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever$334,083
R01 · FY2018 · NS · contact PI
Neuroprotective anti-inflammatory drugs as a novel combination therapy for neurological Rift Valley Fever$326,427
R01 · FY2017 · NS · contact PI
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model$190,277
R21 · FY2016 · NS · contact PI
Mechanisms of Neuropathogenic Rift Valley Fever in a Novel Rat Model$228,575
R21 · FY2015 · NS · contact PI